Skip to main content
Premium Trial:

Request an Annual Quote

Detroit R&D Awarded $1M Phase II SBIR Grant

NEW YORK (GenomeWeb News) – Detroit R&D today announced it has been granted a two-year $1 million Small Business Innovation Research Phase II grant to continue research into protein glycosylation.

The grant from the National Cancer Institute will be used by the company to continue work carried out with a Phase I SBIR grant in 2012 for $300,000, it said. In the Phase I study, Detroit R&D developed glycosylation site-specific antibodies for oncogene proteins and cancer-suppressor proteins, as well as methods for screening anti-cancer drugs. The company developed a microarray-based method for screening glycosylated protein biomarkers in prostate cancer.

With the new funding, the company plans to produce approximately 40 site-specific antibodies for glycosylated receptors and signal transduction pathway proteins. Detroit R&D also plans to elucidate the functions of protein glycosylation in cancer, it said.

The research is anticipated to lead to the development of diagnostics and therapeutics directed at breast, prostate, and pancreatic cancers.

The Phase II study lasts until September 2015.

The Scan

Cell Atlas of Human Lung Development Gives View of Developing Airway

Researchers have generated a cell atlas of human lung development, which they report in Cell.

Study Finds Costs of Genome Sequencing May Limit Utility in Routine Care

Researchers report in the European Journal of Human Genetics that genome sequencing for rare disease diagnoses currently has similar benefits as less expensive exome analysis.

Study Suggests Nursing Mother's Diet Can Impact Offspring's Gut Microbiome

A new Cell Host and Microbe paper finds that mice whose mothers were fed a low-fiber diet during nursing experience lasting microbiota dysbiosis and increased obesity.

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.